Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children

Highlights ► Hepatitis A (HepA) causes large economic burden and is vaccine preventable. ► HepA vaccine was 3- and is now a 2-dose schedule; antibody duration is unknown. ► No differences were observed in antibody levels between 3- and 2-dose schedules. ► Booster dose is not needed at this time, 14...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2013-04, Vol.31 (17), p.2152-2155
Hauptverfasser:	Raczniak, Gregory A, Thomas, Timothy K, Bulkow, Lisa R, Negus, Susan E, Zanis, Carolyn L, Bruce, Michael G, Spradling, Philip R, Teshale, Eyasu H, McMahon, Brian J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent adults Age Allergy and Immunology Antigens Applied microbiology Biological and medical sciences Child Child, Preschool childhood children Cohort Studies Confidence intervals Enterovirus infections Female Follow-Up Studies Fundamental and applied biological sciences. Psychology Health services Hepatitis hepatitis A Hepatitis A - immunology Hepatitis A - prevention & control Hepatitis A Antibodies - immunology Hepatitis A Vaccines - administration & dosage Hepatitis A Vaccines - immunology Hepatitis A virus Human viral diseases Humans Immunization Immunization Schedule Inactivated hepatitis A vaccine Infectious diseases Male Medical sciences Microbiology Miscellaneous people Prospective Studies Proteins risk RNA viruses Time Factors United States Vaccination Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Inactivated - administration & dosage Vaccines, Inactivated - immunology Variance analysis Viral diseases Viral hepatitis Virology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights ► Hepatitis A (HepA) causes large economic burden and is vaccine preventable. ► HepA vaccine was 3- and is now a 2-dose schedule; antibody duration is unknown. ► No differences were observed in antibody levels between 3- and 2-dose schedules. ► Booster dose is not needed at this time, 14 years after initial immunization. ► Plateauing antibody levels suggest longer protection will occur.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2013.02.048